Global Breast Cancer Drug Market Review & Forecast, 2017-2026 -

DUBLIN--()--The "Breast Cancer Drug - Global Market Outlook (2017-2026)" report has been added to's offering.

The Global Breast Cancer Drug market accounted for $14.75 billion in 2017 and is expected to reach $43.27 billion by 2026 growing at a CAGR of 12.7% during the forecast period.

High prevalence of breast cancer, growing R&D investments and rising healthcare expenditure and awareness are some of the key factors influence market growth. However, stringent regulatory guidelines and expiry of patented drugs is restraining the market growth.

Based on Drug, Chemotherapy Drugs segment growth is due to development in the fields of drug delivery and oncology, and increased government funding and initiative to create awareness about cancer diagnosis and treatment. By Geography, North America is going to have a lucrative growth due to prevalence of chronic diseases, growing focus of global pharmaceutical companies in this region.

Some of the key players profiled in the Breast cancer drug Market include Novartis AG, Celgene Corporation, Janssen Global Services LLC, Onyx Pharmaceuticals Inc., AbbVie, Inc., Eli Lilly and Company, Celldex Therapeutics, BioNumerik Pharmaceuticals, Inc., AstraZeneca, Merck & Co., Inc., Genzyme Corporation, MacroGenics, Inc., F. Hoffmann-La Roche Ltd. and Biocon.

What the report offers:

  • Market share assessments for the regional and country level segments
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis etc.
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Key Topics Covered

1 Executive Summary

2 Preface

3 Market Trend Analysis

3.1 Introduction

3.2 Drivers

3.3 Restraints

3.4 Opportunities

3.5 Threats

3.6 Emerging Markets

3.7 Futuristic Market Scenario

4 Porters Five Force Analysis

5 Global Breast Cancer Drug Market, By Type

5.1 Introduction

5.2 Mitotic Inhibitor

5.3 Aromatase Inhibitor

5.4 Hormonal rec

5.5 HER2 Inhibitor

5.6 Anti-Metabolites

5.7 CDK 4/6 Inhibitor

6 Global Breast Cancer Drug Market, By Drug

6.1 Introduction

6.2 Targeted Therapy Drugs

6.2.1 Ado-Trastuzumab Emtansine

6.2.2 Neratinib

6.2.3 Monoclonal Antibodies (mAbs) Bevacizumab Trastuzumab Other Monoclonal Antibodies (mAbs)

6.2.4 Lapatinib

6.2.5 Tyrosine kinase inhibitors

6.3 Chemotherapy Drugs

6.3.1 Antimetabolites Capecitabine Gemcitabine Fluorouracil

6.3.2 Anthracyclines Epirubicin Doxorubicin

6.3.3 Alkylating Agents

6.3.4 Neoadjuvant Chemotherapy

6.3.5 Adjuvant Chemotherapy

6.3.6 Taxanes Docetaxel Paclitaxel

6.3.7 Advanced Breast Cancer

6.3.8 Epothilones

6.4 Hormone Therapy Drugs

6.4.1 Ecstasy and Related Drug (ERD)

6.4.2 Selective Estrogen-Receptor Modulators (SERMs) Tamoxifen Toremifene Raloxifene

6.4.3 Aromatase Inhibitors Anastrozole Letrozole Megestrol

6.4.5 Luteinising Hormone-Releasing Hormone

6.4.6 Other Hormonal Therapies Goserelin Acetate Fulvestrant Fluoxymesterone

6.5 Other Drugs

7 Global Breast Cancer Drug Market, By Distribution Channel

7.1 Introduction

7.2 Clinics

7.3 Online Pharmacies

7.4 Ambulatory Surgical Centers

7.5 Hospitals

7.6 Retail Pharmacies

8 Global Breast Cancer Drug Market, By Drug

8.1 North America

8.1.1 US

8.1.2 Canada

8.1.3 Mexico

8.2 Europe

8.2.1 Germany

8.2.2 France

8.2.3 Italy

8.2.4 UK

8.2.5 Spain

8.3 Asia Pacific

8.3.1 Japan

8.3.2 China

8.3.3 India

8.3.4 Australia

8.3.5 New Zealand

8.3.6 Rest of Asia Pacific

8.4 South America

8.4.1 Argentina

8.4.2 Brazil

8.4.3 Venezuela

8.4.4 Chile

8.4.5 Peru

8.5 Middle East & Africa

8.5.1 UAE

8.5.2 Saudi Arabia

8.5.3 Qatar

8.5.4 Iran

8.5.5 South Africa

8.5.6 Rest of MEA

9 Vendor Landscaping

9.1 Agreements, Partnerships, Collaborations and Joint Ventures

9.2 Acquisitions & Mergers

9.3 New Product Launch

9.4 Expansions

9.5 Other Key Strategies

10 Company Profiles

10.1 Novartis AG

10.2 Celgene Corporation

10.3 Janssen Global Services LLC

10.4 Onyx Pharmaceuticals Inc.

10.5 AbbVie, Inc.

10.6 Eli Lilly and Company

10.7 Celldex Therapeutics

10.8 BioNumerik Pharmaceuticals, Inc.

10.9 AstraZeneca

10.10 Merck & Co., Inc.

10.11 Genzyme Corporation

10.12 MacroGenics, Inc.

10.13 F. Hoffmann-La Roche Ltd.

10.14 Biocon

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900